Home » Stocks » Jaguar Health

Jaguar Health, Inc. (JAGX)

Stock Price: $0.727 USD 0.048 (6.99%)
Updated Aug 5, 2020 3:43 PM EDT - Market open

Stock Price Chart

Key Info

Market Cap 52.74M
Revenue (ttm) 5.05M
Net Income (ttm) -38.17M
Shares Out 32.16M
EPS (ttm) -5.20
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Aug 5, 2020
Last Price $0.727
Previous Close $0.680
Change ($) 0.048
Change (%) 6.99%
Day's Open 0.680
Day's Range 0.670 - 0.744
Day's Volume 5,395,226
52-Week Range 0.351 - 1.790

More Stats

Market Cap 52.74M
Enterprise Value 58.89M
Earnings Date (est) Nov 12, 2020
Ex-Dividend Date n/a
Shares Outstanding 32.16M
Float 16.07M
EPS (basic) -13.31
EPS (diluted) -5.20
FCF / Share -1.41
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 191,092
Short Ratio 0.25
Short % of Float 3.74%
Beta 0.86
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio 10.43
PB Ratio 4.46
Revenue 5.05M
Operating Income -30.83M
Net Income -38.17M
Free Cash Flow -21.29M
Net Cash -6.16M
Net Cash / Share -0.08
Gross Margin -74.84%
Operating Margin -609.92%
Profit Margin -887.10%
FCF Margin -421.31%
ROA -41.14%
ROE -235.60%
ROIC -24,943.20%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (1)

Buy 1
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

$5.00*
Low
5.00
Current: $0.727
High
5.00
Target: 5.00
*Average 12-month price target from 1 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year201920182017201620152014
Revenue5.784.424.360.140.26-
Revenue Growth30.78%1.26%2981.61%-45.23%--
Gross Profit1.961.653.480.090.13-
Operating Income-28.95-30.82-34.25-13.59-12.45-8.32
Net Income-38.54-32.15-21.97-14.73-16.29-8.61
Shares Outstanding4.970.210.040.010.01-
Earnings Per Share-9.01-153.27-531.14-1,417.00-2,834.01-3,400.81
Operating Cash Flow-20.46-22.73-9.82-14.41-14.32-5.36
Capital Expenditures--0.01--0.10--0.06
Free Cash Flow-20.46-22.74-9.82-14.52-14.32-5.41
Cash & Equivalents3.882.570.761.4610.700.85
Total Debt7.5716.0816.413.895.950.82
Net Cash / Debt-3.68-13.52-15.65-2.424.740.03
Assets36.4141.0443.633.5612.414.42
Liabilities15.8426.6626.376.028.015.35
Book Value10.675.3817.26-2.454.40-8.24
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Jaguar Health, Inc.
Country United States
Employees 29
CEO Lisa A. Conte

Stock Information

Ticker Symbol JAGX
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: JAGX

Description

Jaguar Health, Inc., a commercial-stage pharmaceuticals company, focuses on developing gastrointestinal products for human prescription use and animals worldwide. It operates through two reportable segments, Human Health and Animal Health. The company, through its wholly-owned subsidiary, Napo Pharmaceuticals, Inc., focuses on developing and commercializing proprietary human gastrointestinal pharmaceuticals. Its human health product pipelines include crofelemer, which is in Phase III clinical trial for the treatment of cancer therapy-related diarrhea, as well as for the supportive care for inflammatory bowel disease; formulation of crofelemer that is Phase II clinical trial for the treatment of short bowel syndrome, congenital diarrheal disorders, idiopathic/functional diarrhea, and irritable bowel; and SB-300, a second-generation anti-secretory agent for various indications, including cholera. The company's animal health product candidates comprise Canalevia, an animal prescription drug product candidate intended for treatment of chemotherapy-induced diarrhea in dogs; and Equilevia, a non-prescription product for total gut health in equine athletes. In addition, its products include Neonorm Calf and Neonorm Foal. Jaguar Health, Inc. was founded in 2013 and is headquartered in San Francisco, California.